Serum Levels of Intravitreal Bevacizumab After Vitrectomy, Lensectomy and Non-Surgical Controls

References

• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology 2007;114:855–859
   PubMed Web of Science ®Google Scholar
• Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807–4813
   PubMed Web of Science ®Google Scholar
• Sinapis C, Routsias JG, Sinapis A, Sinapis D, Agrogiannis G, Pantopoulou A, et al. Pharmacokinetics of intravitreal bevacizumab (avastin) in rabbits. Clin Ophthalmol 2011;5:697–704
   PubMedGoogle Scholar
• Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124–126
   PubMed Web of Science ®Google Scholar
• Kakinoki M, Miyake T, Sawada O, Sawada T, Kawamura H, Ohji M. The clearance of intravitreal bevacizumab in vitrectomized macaque eyes. Invest Ophthalmol Vis Sci 2011;52:5630
   Google Scholar
• Christoforidis JB, Williams MM, Wang J, Jiang A, Pratt C, Abdel-Rassoul M, et al. Anatomic and pharmacokinetic properties of iIntravitreally placed I-124 radiolabeled bevacizumab and ranibizumab after vitrectomy and lensectomy in a rabbit model. Retina 2013 Feb 12. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415–417
   PubMed Web of Science ®Google Scholar
• Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB Jr. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 1985;92:1601–1605
   PubMed Web of Science ®Google Scholar
• Pearson PA, Hainsworth DP, Ashton P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina 1993;13:326–330
   PubMed Web of Science ®Google Scholar
• Mandell BA, Meredith TA, Aguilar E, El-Massry A, Sawant A, Gardner S. Effects of inflammation and surgery on amikacin levels in the vitreous cavity. Am J Ophthalmol 1993;115:770–774
   PubMed Web of Science ®Google Scholar
• Aguilar HE, Meredith TA, El-Massry A, Shaarawy A, Kincaid M, Dick Y. Vancomycin levels after intravitreal injection. Effects of inflammation and surgery. Retina 1995;15:428–432
   PubMed Web of Science ®Google Scholar
• Shaarawy A, Meredith TA, Kincaid M, Dick J, Aguilar E, Ritchie DJ, et al. Intraocular injection of ceftazidime. Effects of inflammation and surgery. Retina 1995;15:433–438
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;359: 427–434
   Google Scholar
• Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan-and bevacizumab-based therapy. J Clin Oncol 2005;23:2574–2576
   PubMed Web of Science ®Google Scholar
• Lordick F, Neinitz H, Thelsen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 2006;64:1295–1298
   PubMed Web of Science ®Google Scholar
• Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009;62:707–709
   PubMed Web of Science ®Google Scholar
• , Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–1398
   PubMed Web of Science ®Google Scholar
• Christoforidis JB, Rickets R, Pratt C, Pierce J, Bean S, Wells M, et al. The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. Clin Ophthalmol 2012;6:61–69
   PubMedGoogle Scholar
• Christoforidis JB, Wang J, Jiang A, Willard J, Pratt C, Abdel-Rasoul M, Powell H, et al. The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing. Clin Ophthalmol 2013;7:185--191
   PubMedGoogle Scholar
• Kim MJ, Han ES, Kim J, Kim TW. Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit. J Ocul Pharmacol Ther 2010;26:49–53
   PubMed Web of Science ®Google Scholar
• Grad S, Ertel W, Keel M, Infanger M, Vonderschmitt DJ, Maly FE. Strongly enhanced serum levels of vascular endothelial growth factor (VEGF) after polytrauma and burn. Clin Chem Lab Med 1998;36:379–383
   PubMed Web of Science ®Google Scholar
• Larsson A, Skoldenberg E, Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 2002;4:107–110
   Google Scholar
• Douzinas E, Betrosian A, Livaditi O, Flevari K, Kanni T, Mouktaroudi M, et al. Hypoxemic resuscitation after hemorrhagic shock is accompanied by reduced serum levels of angiopoietin-2. Cytokine 2009;47:82–84
   PubMed Web of Science ®Google Scholar
• Rich RM, Rosenfeld PJ, Pulafito CA, Dubovy SR, Davis JL, Flynn HW Jr, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495–511
   PubMed Web of Science ®Google Scholar
• Gisladottir S, Loftsson T, Stefansson E. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefes Arch Clin Exp Ophthalmol 2009;247:1677–1684
   PubMed Web of Science ®Google Scholar
• Stefansson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147–163
   PubMed Web of Science ®Google Scholar
• , The IVAN Study InvestigatorsChakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399–1411
   PubMed Web of Science ®Google Scholar
• Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273–1279
   PubMed Web of Science ®Google Scholar
• Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009;62:707–709
   PubMed Web of Science ®Google Scholar
• Zawacki WJ, Walker TG, DeVasher E, Halpern EF, Waltman AC, Wicky ST, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol 2009;20:624–627
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173–180
   PubMed Web of Science ®Google Scholar
• Chew EY, Sperduto RD, Milton RC, Clemons TE, Gensler GR, Bressler SB, et al. Risk of advanced age-related macular degeneration following cataract surgery in the age-related eye disease study: AREDS report 25. Ophthalmology 2009;116:297–303
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Hernandez E, Fliesler SJ, Alvarez J, Pflugfelder ME, Forster RK. Intravitreal vancomycin. Arch Ophthalmol 1987;105:831–837
   PubMed Web of Science ®Google Scholar
• Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2013;98:F170--F174
   Google Scholar
• Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011;31:1877–1884
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Webb W, Van Hoy M. Pharmacokinetics and retinal distribution of AMD rhufab V2 after intravitreal administration in rabbits. AAPS Pharm Sci 1999;2:3207
   Google Scholar
• Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-a in patients with choroidal neovascularization. Ophthalmology 2008;115:1750–1755
   PubMed Web of Science ®Google Scholar
• Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthlamol 2008;146:508–512
   PubMed Web of Science ®Google Scholar
• Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears MI, editor. Pharmacology of the eye. New York (NY): Springer-Verlag; 1984. pp 19–116
   Google Scholar